CAS 72496-41-4

Pirarubicina

Descripción:

Pirarubicina, con el número CAS 72496-41-4, es un antibiótico antraciclínico que se utiliza principalmente como agente antineoplásico en la terapia del cáncer. Está estructuralmente relacionado con la doxorubicina y exhibe mecanismos de acción similares, principalmente intercalándose en el ADN, inhibiendo así la síntesis de ADN y ARN, lo que lleva a la muerte celular. Pirarubicina es particularmente efectivo contra varios tipos de cáncer, incluyendo el cáncer de mama y la leucemia. Su perfil farmacológico incluye un nivel de citotoxicidad moderado a alto, y a menudo se administra por vía intravenosa. El fármaco es conocido por sus posibles efectos secundarios, que pueden incluir cardiotoxicidad, mielosupresión y trastornos gastrointestinales. Debido a su estructura química, Pirarubicina también puede generar especies reactivas de oxígeno, contribuyendo a sus efectos anticancerígenos. El compuesto se utiliza típicamente en combinación con otros agentes quimioterapéuticos para mejorar la eficacia terapéutica mientras se maneja la resistencia. Al igual que con todos los agentes quimioterapéuticos, el monitoreo cuidadoso de los pacientes es esencial para mitigar los efectos adversos y optimizar los resultados del tratamiento.

Fórmula: C₃₂H₃₇NO₁₂

InChI: InChI=1/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19?,21+,22-,31+,32-/m0/s1

Clave InChI: InChIKey=KMSKQZKKOZQFFG-YXRRJAAWSA-N

SMILES: O([C@@H]1C2=C(C(O)=C3C(=C2O)C(=O)C=4C(C3=O)=CC=CC4OC)C[C@](C(CO)=O)(O)C1)[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5

Sinónimos:

• (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2S)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
• (2''R)-4'-O-Tetrahydropyranyladriamycin
• (2′′R)-4′-O-Tetrahydropyranyladriamycin
• (2′′R)-4′-O-Tetrahydropyranyldoxorubicin
• (3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
• (8S,10S)-10-((3-Amino-2,3,6-trideoxy-4-O-(2R-tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
• (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• 1609Rb
• 4'-O-Tetrahydropyranyladriamycin
• 4'-O-Tetrahydropyranyldoxorubicin
• 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• Pinorubicin
• Pirarubicin Hydrochloride
• Pirarubicin [INN:JAN]
• Pirarubicina
• Pirarubicina [Spanish]
• Pirarubicine
• Pirarubicine [French]
• Pirarubicinum
• Pirarubicinum [Latin]
• THP-adriamycin
• Therarubicin
• (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
• (8S)-10α-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• l)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hy
• (7S,9S)-7-((2R,4S,5S,6S)-4-amino-6-methyl-5-((R)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
• 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-y
• (8s-cis)-droxyacetyl)-1-methoxy
• (8S)-10-[(2S,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
• 5,12-Naphthacenedione, 10-3-amino-2,3,6-trideoxy-4-O-(2R)-tetrahydro-2H-pyran-2-yl-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• THP-ADM
• Pirarubicin(THP-AdriaMycin)
• THEPRUBICIN
• Therarubiein
• Pirarubicin(BICINS)
• Pirabucin
• PIRARUBICIN
• (8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
• (8S,10S)-10α-[[3-Amino-4-O-(tetrahydro-2H-pyran-2-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-hydroxyacetyl-1-methoxy-5,12-naphthacenedione

(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

CAS: 72496-41-4

Fórmula: C₃₂H₃₇NO₁₂

Pureza: 97%

Forma y color: Solid

Peso molecular: 627.6357

Ref: IN-DA0065SG

Pirarubicin

CAS: 72496-41-4

Pirarubicin

Pureza: ≥95%

Peso molecular: 627.64g/mol

Ref: 54-BUP10616

(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-Methyl-5-(((R)-Tetrahydro-2H-Pyran-2-Yl)Oxy)Tetrahydro-2H-Pyran-2-Yl)Oxy)-6,8,11-Trihydroxy-8-(2-Hydroxyacetyl)-1-Methoxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione

CAS: 72496-41-4

(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-Methyl-5-(((R)-Tetrahydro-2H-Pyran-2-Yl)Oxy)Tetrahydro-2H-Pyran-2-Yl)Oxy)-6,8,11-Trihydroxy-8-(2-Hydroxyacetyl)-1-Methoxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione

Pureza: 98%

Peso molecular: 627.64g/mol

Ref: 54-OR1023344

Pirarubicin

CAS: 72496-41-4

Pirarubicin (Theprubicin), an anthracycline antibiotic, inhibits DNA/RNA synthesis and is used as an antineoplastic.

Fórmula: C₃₂H₃₇NO₁₂

Pureza: 97.80% - 99.15%

Forma y color: Red Crystalline Powder

Peso molecular: 627.64

Ref: TM-T6628

Pirarubicin

CAS: 72496-41-4

Fórmula: C₃₂H₃₇NO₁₂

Pureza: ≥ 95%

Forma y color: Red to orange powder

Peso molecular: 627.64

Ref: 7W-GA1643

Pirarubicin

CAS: 72496-41-4

Antibiotic of anthracycline class; DNA synthesis inhibitor

Fórmula: C₃₂H₃₇NO₁₂

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 627.64 g/mol

Ref: 3D-FP27079

Pirarubicin

Producto controlado

CAS: 72496-41-4

Applications Structural analog of Doxorubicin. Antineoplastic.
References Umezawa, H., et al.: J. Antibiot., 32, 1082 (1979), Majima, H., et al.: Biomed. Pharmacother., 41, 237 (1987), Miller, A.A., et al.: Cancer Res., 47, 1461 (1987), Fallik, D., et al.: Ann. Ocol., 14, 856 (2003),

Fórmula: C₃₂H₃₇NO₁₂

Forma y color: Neat

Peso molecular: 627.64

Ref: TR-P501500